Geopolitical and economic turmoil has changed the outlook for companies across all industry sectors. For investors who own shares in them, the question now is whether these stocks are worth holding and where their prices will go from h...
GNS — Genus Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMid CapSucker Stock
- £1.77bn
- £1.91bn
- £574.30m
- 42
- 18
- 14
- 14
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.81 | ||
| PEG Ratio (f) | 3.71 | ||
| EPS Growth (f) | 8.42% | ||
| Dividend Yield (f) | 1.3% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.47 | ||
| Price to Tang. Book | 5.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.1 | ||
| EV to EBITDA | 26.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.78% | ||
| Return on Equity | 7.07% | ||
| Operating Margin | 6.34% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 459.1 | 470.3 | 488.5 | 551.4 | 574.3 | 572.58 | 605.63 | 8.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +7.95 | -9.8 | -3.06 | +25.19 | +51.1 | -12.09 | +11.29 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for GNS
It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Genus (LON:GNS) will go from her...
With areas of the economy continuing to recover from the impact of Covid, stock market investors have been laser-focused on the share prices of some of the UK’s biggest companies - including Genus (LON:GNS). Genus is one of just 200 UK...
Analysts have been under intense pressure in recent months as they try to make sense of the impact of Covid-19 on companies like Genus (LON:GNS). As one of just 200 shares in the UK market valued at more than £1.0 billion (its market c...
It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Genus (LON:GNS) will go from her...
Profile Summary
Genus PLC is a United Kingdom-based animal genetics company. The Company provides farmers with genetics that enable them to produce animal protein for breeding pigs and cattle, in the form of meat and milk. The Company’s operating segments includes Genus PIC, Genus ABS and Research and Development. The Genus PIC segment is engaged in porcine sales business. The Genus ABS segment is engaged in bovine sales business. The Company's development activities include developing and maintaining its porcine genetic nucleus herd and bovine pre-stud herds. The Company operates approximately around 25 countries on six continents, with research laboratories located in Madison, Wisconsin, United States.
Directors
- Iain Ferguson NEC (65)
- Stephen Wilson CEO
- Alison Henriksen CFO
- Elena Rice CSO
- Dan Hartley GCN
- Angelle Rosata DHR
- Bill Christianson OTH
- Jerry Thompson OTH
- Nate Zwald OTH
- Jason Chin NID
- Lysanne Gray NID
- Lesley Knox NID
- Lykele van der Broek NID
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- September 26th, 1994
- Public Since
- July 6th, 2000
- No. of Employees
- 3,096
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 65,770,066
- Address
- Matrix House, Basing View, BASINGSTOKE, RG21 4DZ
- Web
- https://www.genusplc.com
- Phone
- +44 1256347100
- Contact
- Charles Ryland
- Auditors
- Deloitte LLP
Latest News for GNS
Upcoming Events for GNS
Full Year 2022 Genus PLC Earnings Release
Similar to GNS
4Basebio
London Stock Exchange
4d Pharma
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
FAQ
What is the Genus share price?
As of Today at 07:09 UTC, shares in Genus are trading at 2,684.00p. This share price information is delayed by 15 minutes.
How has the Genus share price performed this year?
Shares in Genus last closed at 2,684.00p and the price had moved by -45.02% over the past 365 days. In terms of relative price strength the Genus share price has underperformed the FTSE All Share Index by -46.12% over the past year.
What are the analyst and broker recommendations for Genus?
The overall consensus recommendation for Genus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Genus dividend yield?
The Genus dividend yield is 1.19% based on the trailing twelve month period.
Does Genus pay a dividend?
Last year, Genus paid a total dividend of £0.32, and it currently has a trailing dividend yield of 1.19%. We do not have any data on when Genus is to next pay dividends.
When does Genus next pay dividends?
We do not have data on when Genus is to next pay dividends. The historic dividend yield on Genus shares is currently 1.19%.
How do I buy Genus shares?
To buy shares in Genus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genus?
As of the previous close price of 2,684.00p, shares in Genus had a market capitalisation of £1.77bn.
Where are Genus shares listed?
Here are the trading details for Genus:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GNS
What kind of share is Genus?
Based on an overall assessment of its quality, value and momentum Genus is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genus share price forecast for 2022?
The analyst consensus target price for shares in Genus is 4,318.14p. That is 60.88% above the last closing price of 2,684.00p.
Analysts covering Genus currently have a consensus Earnings Per Share (EPS) forecast of £0.85 for the next financial year.
What is the trend in the Genus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genus. Over the past six months, its share price has underperformed the FTSE All Share Index by -50.31%.
As of the last closing price of 2,684.00p, shares in Genus were trading -38.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genus PE Ratio?
The Genus PE ratio based on its reported earnings over the past 12 months is 28.81. The shares last closed at 2,684.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genus?
Genus' management team is headed by:
- Iain Ferguson - NEC
- Stephen Wilson - CEO
- Alison Henriksen - CFO
- Elena Rice - CSO
- Dan Hartley - GCN
- Angelle Rosata - DHR
- Bill Christianson - OTH
- Jerry Thompson - OTH
- Nate Zwald - OTH
- Jason Chin - NID
- Lysanne Gray - NID
- Lesley Knox - NID
- Lykele van der Broek - NID